Europe does not need another warning. It needs a different way of responding.
Across Europe, a silent epidemic has taken root in the liver — shaped by the foods people eat, the alcohol cultures they inhabit, and the healthcare systems that have not yet learned to look. A landmark study led by the Barcelona Institute for Global Health, drawing on the work of more than 75 researchers across 30 countries, reveals that chronic liver disease now claims 287,000 lives prematurely each year on the continent, ranking second only to heart disease in working years stolen. What makes this crisis distinctive is not merely its scale, but its invisibility: most of those affected do not know it, and most health systems are not yet designed to find them. The researchers argue that this is not a story of individual failure, but of collective choices — in food policy, alcohol culture, and the architecture of care — that can still be unmade.
- One in three people across the EU and UK are estimated to carry metabolic liver disease without knowing it, while alcohol drives 40% of the continent's 287,000 annual liver-related deaths — making Europe both the world's heaviest drinker and its most liver-burdened region.
- The crisis strikes hardest at working-age men and socially disadvantaged populations, with liver disease advancing to cirrhosis and cancer decades earlier than most chronic conditions — yet primary care systems still screen routinely for cholesterol and blood pressure, not liver fibrosis.
- Stigma compounds the medical failure: patients with liver disease are routinely treated as architects of their own suffering, a moral judgment that suppresses care-seeking, distorts policy priorities, and leaves the disease chronically under-resourced.
- A consortium of researchers is calling for a fundamental restructuring — integrating liver health into obesity, diabetes, cardiovascular, and alcohol policy frameworks, expanding screening in primary care, and confronting the commercial forces that normalize harmful consumption.
- The window is narrowing: researchers warn that Europe must act before advanced disease becomes the default point of diagnosis, with the findings released at a major hepatology congress in Barcelona to signal the urgency of systemic response.
A consortium of more than 75 researchers from 30 countries, led by the Barcelona Institute for Global Health, has published a sweeping assessment of Europe's liver disease crisis in The Lancet Regional Health – Europe. Their conclusion is unsparing: chronic liver disease has become a silent epidemic, now second only to heart disease as the leading cause of working years lost across the continent. Approximately 287,000 people die prematurely from it each year — and much of that toll remains invisible, undiagnosed, and preventable.
The disease burden has shifted. Metabolic dysfunction-associated steatotic liver disease, or MASLD, now affects an estimated one in three people in the EU and UK, developing quietly and going undetected until serious damage is done. Alcohol compounds the picture: Europe leads the world in per-capita consumption and heavy episodic drinking, and alcohol accounts for roughly 40 percent of all liver-related deaths annually. When metabolic risk factors and alcohol combine, end-stage liver disease and liver cancer emerge in working-age populations — often decades before other chronic conditions would typically appear. Viral hepatitis adds further weight, accounting for the majority of deaths from hepatitis B and C across the region.
The burden falls hardest on men and socially disadvantaged populations, deepening existing inequities. Yet primary care systems across Europe screen routinely for blood pressure and cholesterol — not for liver fibrosis, the early warning sign that could interrupt the path to cirrhosis and cancer. Jeffrey Lazarus of ISGlobal's Public Health Liver Group argues that Europe does not need another warning; it needs a fundamentally different approach. Liver disease must stop being treated as a specialist concern and start being understood as a consequence of diet, alcohol policy, obesity, and sedentary living.
Patient advocates have highlighted another barrier: stigma. People with liver disease frequently encounter the assumption that their condition reflects personal failure rather than medical reality — a judgment that shapes whether they seek care and whether policy-makers prioritize their needs. The researchers call for concrete change: integrating liver health into non-communicable disease and cancer prevention strategies, expanding screening, strengthening surveillance, improving access to treatment and harm reduction, and directly confronting the commercial drivers of harm in food and alcohol industries.
The research was presented at a flagship event in Barcelona ahead of the European Association for the Study of the Liver Congress. The question it leaves open is whether Europe's governments and health institutions will meet the evidence with the systemic response it demands — before advanced disease becomes the continent's default point of diagnosis.
A consortium of more than 75 researchers from 30 countries has published a stark assessment of Europe's liver disease crisis in The Lancet Regional Health – Europe, led by the Barcelona Institute for Global Health. The finding is unambiguous: chronic liver disease has become a silent epidemic, now ranking second only to heart disease as the leading cause of working years lost across the continent. What makes this particularly urgent is not just the scale—roughly 287,000 premature deaths annually—but the fact that so much of it remains invisible, undiagnosed, and preventable.
The disease burden has shifted in recent years. Metabolic dysfunction-associated steatotic liver disease, or MASLD, is now reshaping Europe's liver health landscape. One in three people in the EU and UK are estimated to be living with this condition, which develops silently and often goes undetected until significant damage has occurred. Alcohol remains a major driver as well. Europe has the highest per-capita alcohol consumption in the world, the highest rates of heavy episodic drinking, and the lowest abstention rates globally. Alcohol accounts for roughly 40 percent of all liver-related deaths annually, though researchers suspect the true figure is higher. When combined with obesity and other metabolic risk factors, the result is a cascade of end-stage liver disease and liver cancer occurring in working-age populations—often decades before other chronic conditions would typically strike.
Viral hepatitis compounds the problem. Hepatitis B and C together account for more than 85 percent of the nearly 57,000 annual deaths from HIV, tuberculosis, and viral hepatitis infections across the EU and European Economic Area. The disease burden falls heaviest on men and socially disadvantaged populations, deepening existing health inequities. Yet despite these numbers, millions of people with chronic liver disease remain undiagnosed. Primary care systems across Europe routinely screen for blood pressure, cholesterol, and weight, but not for liver fibrosis—a critical early warning sign that could prevent progression to cirrhosis and cancer.
The researchers argue that Europe's response has been too narrow. Jeffrey Lazarus, who chairs the Public Health Liver Group at ISGlobal, put it plainly: Europe does not need another warning that liver disease is worsening. It needs a fundamentally different approach. The current system treats liver disease as a specialist concern, confined to hepatologists. But the roots of the problem run through diet, alcohol policy, obesity prevention, diabetes management, and cardiovascular health. When we talk about ultraprocessed food and sedentary lifestyles, Lazarus notes, we are essentially talking about liver disease risk. Primary care must change. Screening protocols must expand. Public health policies must address the commercial drivers of harm—the food industry, alcohol marketing, and the normalization of unhealthy consumption patterns.
Patient advocates have raised another critical issue: stigma. Individuals with liver disease frequently encounter the assumption that their condition is purely a result of personal choice, a moral failing rather than a medical reality. This stigma directly influences whether people seek care, whether they engage with treatment, and ultimately their health outcomes. It also shapes policy priorities, keeping liver disease persistently under-recognized and under-resourced. The researchers emphasize that metabolic liver disease, viral hepatitis, and alcohol-related liver disease disproportionately affect vulnerable populations—those with fewer resources, less access to healthcare, and less power to influence the commercial and policy environments that shape their risk.
The Series, comprising four papers and four accompanying comments, examines liver disease from multiple angles: diagnostic innovation and care models, metabolic liver disease policy readiness, alcohol-related disease, and viral hepatitis elimination. The recommendations are concrete. Europe needs to integrate liver health into non-communicable disease and cancer prevention strategies. Liver disease responses must align with policies on diabetes, obesity, alcohol, cardiovascular disease, nutrition, and physical activity. Surveillance systems must strengthen. Access to treatment and harm reduction services must improve. Alcohol policies must become more robust, and commercial drivers of harm must be confronted directly. Stigma must be addressed, and barriers affecting underserved communities must be dismantled.
The window for action is narrowing. Lazarus concludes that ending chronic liver disease as a public health threat in Europe is possible, but only if the continent acts before advanced disease becomes the default point of diagnosis. The research was released during a flagship event in Barcelona ahead of the European Association for the Study of the Liver Congress, signaling that this is not a marginal concern but a central challenge for European health systems. The question now is whether Europe's governments and health institutions will respond with the systemic change the evidence demands.
Notable Quotes
When we talk about ultraprocessed food, alcoholic drinks and unhealthy diets, we are essentially talking about liver disease risk. We need stronger public health policies and interventions to address this disease burden.— Jeffrey V. Lazarus, Professor at CUNY Graduate School of Public Health and Head of the Public Health Liver Group at ISGlobal
The stigma from this lack of context directly influences care-seeking, engagement, and health outcomes, while also shaping policy priorities and contributing to the persistent under-recognition of liver disease.— Patient advocates Jeff McIntyre, Gina Bartes, and Raquel Peck
The Hearth Conversation Another angle on the story
Why does liver disease matter more now than it did ten years ago?
The disease itself hasn't changed, but what's driving it has. Metabolic liver disease—the kind linked to obesity, diabetes, and poor diet—has exploded. It's now affecting one in three people in the EU. That's a fundamentally different epidemic than the one we were managing before.
But people know about obesity and diabetes. Why isn't that already triggering alarm?
Because liver disease is invisible. You can have significant fibrosis—scarring—and feel completely fine. There's no pain, no obvious symptom. People get screened for cholesterol and blood pressure routinely, but almost never for liver fibrosis. By the time someone finds out they have liver disease, they're often already in advanced stages.
The report mentions stigma as a barrier. How does that actually work?
If you have liver disease, people assume you drank too much or ate too much—that it's your fault. That shame keeps people from seeking care. They don't want to be judged. And policymakers internalize that same judgment, so liver disease stays underfunded and under-prioritized compared to diseases seen as more "legitimate."
Is this really a liver problem, or is it a broader public health problem?
That's exactly the point the researchers are making. It's not a liver problem. It's a problem with how we eat, how much we drink, how sedentary we are, and how little we regulate the industries profiting from those behaviors. Treating it as a liver specialist issue misses the entire picture.
What would actually change if Europe listened to these recommendations?
Primary care would screen for liver fibrosis as routinely as they check blood pressure. Alcohol policies would tighten. Food industry marketing would face real constraints. Treatment would be accessible and non-judgmental. And vulnerable populations—the ones hit hardest—would finally get resources directed toward them instead than away from them.
Is there any reason to think this will actually happen?
The research is rigorous and the case is clear. But it requires governments to confront powerful industries and to reframe liver disease as a collective responsibility, not an individual failing. That's a political choice, not a medical one.